The company said, "As of December 31, 2022, Rain had $130.5M in cash, cash equivalents and short-term investments. Rain will not provide guidance on cash runway at this time. Rain will continue to assess its cash runway and provide further guidance, if appropriate, after the release of MANTRA topline results in the second quarter of this year."
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RAIN:
- Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
- TipRanks ‘Perfect 10’ List: There’s an Opportunity Brewing in These 2 Stocks
- Rain Oncology delayed data could be positive sign, says JonesResearch
- Rain Oncology to Participate in the 2023 Citi Virtual Oncology Leadership Summit
- UPDATE – Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue